Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DQCJ39
|
|||
Drug Name |
IMT-002
|
|||
Synonyms |
2799-15-7; D-alpha-Methyl DOPA; D-Methyldopa; (2R)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; Methyldopa, D-; (R)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; 8K91SZC8W9; 3-Hydroxy-alpha-Methyl-D-Tyrosine; L-Methyldopa; (+)-alpha-Methyldopa; UNII-8K91SZC8W9; CAS-555-30-6; D-(3,4-Dihydroxyphenyl)-2-methylalanine; Lopac-M-129; D- alpha -Methyl DOPA; Lopac-M-7277; D-3-(3,4-Dihydroxyphenyl)-2-methylalanine; D-.ALPHA.-METHYLDOPA; SCHEMBL1321546; CHEMBL1452561; METHYLDOPA ANHYDROUS, D-; (+)-.ALPHA.-METHYLDOPA; DTXSID50859484; IMT-002; AKOS030242221; NCGC00015631-01; NCGC00015631-02; NCGC00016510-01; NCGC00016510-02; NCGC00016510-03; NCGC00094724-01; NCGC00094724-02; METHYLDOPA IMPURITY D [EP IMPURITY]; D-TYROSINE, 3-HYDROXY-.ALPHA.-METHYL-; EN300-225307; Alanine, 3-(3,4-dihydroxyphenyl)-2-methyl-, D-; J-016939; Q27270669; D-.ALPHA.-METHYL-3-(3,4-DIHYDROXYPHENYL)ALANINE; Z1508927176; (2R)-2-amino-3-(3,4-dihydroxyphenyl)-2-methyl-propanoic acid; (2R)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoicacid
Click to Show/Hide
|
|||
Drug Type |
Small molecule
|
|||
Indication | Type-1 diabetes [ICD-11: 5A10] | Phase 1 | [1] | |
Company |
IM Therapeutics
|
|||
Structure |
Download2D MOL |
|||
Formula |
C10H13NO4
|
|||
Canonical SMILES |
CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N
|
|||
InChI |
InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m1/s1
|
|||
InChIKey |
CJCSPKMFHVPWAR-SNVBAGLBSA-N
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04625595) A Phase 1b, Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose (MAD) Study to Assess the Steady-State Pharmacokinetics and DQ8 Blocking Efficacy of Orally Administered IMT-002 in Patients With Type 1 Diabetes and HLA-DQ8. U.S.National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.